BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mediwatch Secures FDA Marketing Approval For Portascan(R)


10/19/2005 5:09:43 PM

RUGBY, England, Jan. 20 /PRNewswire/ -- Mediwatch, the innovative UK manufacturer of high tech screening and diagnostic systems for urological disorders, announced today that it has received marketing approval from the US Food and Drug Administration (FDA) for the Portascan(R) portable bladder scanner in the USA.

The state-of-the-art portable diagnostic will be used to screen patients suffering from prostate and bladder disorders, incontinence and those requiring catheterization. Doctors' offices, outpatient clinics, hospital emergency departments and nursing homes are all potential users of the Portascan, where its level of accuracy gives it a major advantage over its competitors This approval provides Mediwatch with access to the lucrative US bladder screening market, currently valued at between $15 and $20 million per annum.

Commenting on this development, Philip Stimpson, CEO, said, "Breaking into the US market represents a significant milestone for Mediwatch. We are in advanced stages to conclude a distribution agreement with a large, well- established international company that is already selling into closely related markets. Although this is our first venture into the US, we have already signed similar agreements with multi-nationals to distribute our products across Europe."

Issued on behalf of Mediwatch by De Facto Communications plc

Mediwatch

CONTACT: Yvonne Alexander of De Facto, +1-44-20-7496-3316, ory.alexander@defacto.com; or Philip Stimpson of Mediwatch, +44-788-547-888, orphilip.stimpson@mediwatch.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES